1 Title page

2 Outpatient and Home Pulmonary Rehabilitation Program Post COVID-19: A

3 study protocol for clinical trial

4 Short title: Outpatient and Home Pulmonary Rehabilitation Program Post
 5 COVID-19

Luis V. F. Oliveira^{1*¶}, Miriã C. Oliveira^{1¶}, Maria E. M. Lino²; Marilucia M. Carrijo¹, 6 João Pedro R. Afonso¹, Ricardo S. Moura¹, Adriano L. Fonseca¹, Daniela R. P. 7 Fonseca¹, Luis Felipe R. J. Oliveira¹, Letícia S. Galvão², Bianca M. Reis², 8 Raphael H. C. O. Diniz², Rubens R. Bernardes², Elisângela R. P. Póvoa², 9 Anderson S. Silva³, Dante B. Santos¹, Vinicius Z Maldaner¹, Jean Carlos 10 Coutinho¹, Guilherme Pacheco Modesto¹, Iransé Oliveira-Silva¹, Rodrigo A. B. 11 Lopes Martins¹, Patrícia S. L. Lopes Martins¹, Claudia S. Oliveira¹, Gerson 12 13 Cipriano Júnior¹, Rodolfo P Vieira¹, Renata K. Palma^{1,4}, Larissa R. Alves¹, Giuseppe Insalaco⁵. 14

15

¹Human Movement and Rehabilitation Post Graduate Program, Evangelical
 University of Goiás – UniEVANGÉLICA, Anápolis (GO), Brazil.

¹⁸ ²Scientific Initiation Program, Evangelical University of Goiás ¹⁹ UniEVANGÉLICA. Anápolis (GO), Brazil

³Health Sciences Post Graduate Program, Faculty of Medical Sciences, Santa
Casa de São Paulo, São Paulo (SP), Brazil.

⁴Facultad de Ciencias Experimentales. Universidad Francisco de Vitoria,
 Madrid, Spain.

⁵Institute for Biomedical Research and Innovation, National Research Council CNR, Palermo (SI), Italy.

26

27 *Corresponding author

28 NOE: That review and should not be used to guide clinical practice.

29 Funding

This study protocol was approved in an emergency public call from the 30 government of the State of Goiás (Brazil): Public Call: 06/2020 - Mapping of 31 32 Proposals to Address Covid-19. Administrative process no.: 202010267000277. Research project: "COVID-19 Outpatient and Home Pulmonary Rehabilitation 33 34 Program" from the Goiás State Research Support Foundation - FAPEG, Brazil. The full name of the funder is: Fundação de Amparo a Pesquisa do Estado de 35 Goiás – FAPEG, Goiania (GO), Brazil. Website: http://www.fapeg.go.gov.br. 36 The authors thank Evangelical University of Goiás - UniEVANGÉLICA for the 37 partial support to the development of this research. The funders had and will not 38 have a role in the study design, data collection and analysis, decision to publish, 39 or preparation of the manuscript. The funding letter has been attached as a 40 supporting file. 41

ASS receives grants of Coordenacao de Apoio ao Pessoal de Nível Superior 42 (CAPES/PROSUP); JPRA and RSM receives grants of Fundação de Amparo a 43 44 Pesquisa (FAPEG), Goiás (GO), Brazil; LVFO receive grants Research Productivity, modality PQ1D; process no. 312731/2018-3 of Conselho Nacional 45 de Desenvolvimento Científico e Tecnologico (local acronym CNPg), Brazil. 46 RPV receive grants Research Productivity, modality PQII; process no. 47 313299/2018-8 of Conselho Nacional de Desenvolvimento Científico e 48 Tecnologico (local acronym CNPq), Brazil. CSO receive grants Research 49 Productivity, modality PQII; process no. 310904/2021-8 of Conselho Nacional 50 de Desenvolvimento Científico e Tecnologico (local acronym CNPg), Brazil. 51 RABLM receive grants Research Productivity, modality PQ1D; process no. 52 53 309920/2019-1 of Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (local acronym CNPq), Brazil. GCJ receive grants Research 54 Productivity, modality PQII; process no. 315604/2021-2 of Conselho Nacional 55 de Desenvolvimento Científico e Tecnologico (local acronym CNPg), Brazil. GI 56 is a senior researcher at the Institute for Biomedical Research and Innovation, 57 National Research Council - CNR, Palermo (SI), Italy. 58

- 59
- 60

61 Competing interests

62 The authors have declared that no competing interests exist.

63 Data AvailabilityStatement

All relevant data from this study will be made available upon study completion.

65 Abstract

66 Background

67 The coronavirus disease 2019 (COVID-19) is a widespread, highly contagious inflammatory process that causes respiratory, physical and psychological 68 69 dysfunction. COVID-19 mainly affects the respiratory system and evolves in the acute phase from mild cases with common symptoms, such as fever, cough, 70 71 and fatigue, to the moderate-to-severe form, causing massive alveolar damage 72 resulting in dyspnea and hypoxemia that can rapidly progress to pneumonia, and acute respiratory distress syndrome. The acute form usually causes severe 73 74 pulmonary sequelae such as pulmonary fibrosis or progression to organ failure, leading to worsening metabolic dysfunction and/or death. 75

76 Purpose

To verify the effects of an outpatient and home pulmonary rehabilitation program (PRP) on clinical symptoms, pulmonary function, physical activity level, functional status, autonomic activity, peripheral muscle strength, static and functional balance, functional mobility, anxiety and depression, post-traumatic stress, health-related quality of life, and survival of patients with sequelae from COVID-19.

83 Methods

This study will be a cohort, parallel, two-arm multicentric study, to be carried out in three clinical centers, with blind evaluation, with 06 weeks of training and follow-up. This study was designed according to the recommendations of the CONSORT statement. To be involved in this clinical study, according to the inclusion criteria, women and men aged between 16 and 75 years affected by COVID-19. The proposed PRP is based on the guidelines recommended by the

Global Initiative for Chronic Obstructive Lung Disease and, consists of a
combination of aerobic and muscle strengthening exercises, lasting six weeks,
with a frequency of three times a week.

93 Discussion

In patients infected with COVID-19 with persistent symptoms and sequelae,
PRP mainly seeks to improve dyspnea, relieve anxiety and depression, prevent,
and reduce complications and/or dysfunctions, reduce morbidity and mortality,
and improve health-related quality of life.

Trial registration: This study was registered at clinicaltrials.gov (ID: COVID-19
PULMONARY REHAB NCT04982042).

100 Introduction

The disease caused by coronavirus disease 2019 (COVID-19) is 101 102 characterized by a widespread, highly contagious inflammatory process that causes respiratory, physical, and psychological dysfunction in patients. 103 COVID19 emerged in December 2019 in Wuhan, Hubei province, China, and 104 alarmingly spread worldwide, with the growth in the number of cases and 105 deaths being considered a global outbreak with a dramatic impact. It was 106 107 declared a pandemic by the World Health Organization (WHO) in March 2020 108 [1].

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), caused by COVID-19, mainly affects the respiratory system and evolves in the acute phase from mild cases with common symptoms, such as fever, cough, and fatigue, to the moderate-to-severe form, causing massive alveolar damage resulting in dyspnea and hypoxemia that can rapidly progress to pneumonia, acute respiratory distress syndrome (ARDS), difficult-to-correct metabolic acidosis, and clotting disorders. The acute form of COVID-19 usually causes

severe pulmonary sequelae such as pulmonary fibrosis or progression to 116 117 multiple organ failure, leading to worsening metabolic dysfunction and/or death [2-4]. Hospital admission rates for COVID-19 patients have been difficult to 118 estimate because they depend on the prevalence of community testing and 119 120 admission criteria, which vary between countries [5]. The WHO reported that patients with COVID-19 develop signs and symptoms after 5 to 6 days of 121 122 infection, although asymptomatic cases range from 27% to 40% of cases, as 123 indicated by pre-vaccination data [6]. The mean time interval from the onset of 124 the first symptoms of dyspnea to hospitalization and ARDS has been 5 to 8 125 days, respectively, and in this same period, the scientific literature estimates 126 that 80% of cases were asymptomatic or mild, 15% severe, and 5% critical [7-9]. Elderly, immunosuppressed, and hypertensive people with underlying 127 128 chronic heart or lung disease are at a greater risk of developing the severe form of COVID-19, requiring admission to an intensive care unit (ICU) and 129 progressing to a worse prognosis [10,11]. 130

131 In view of the broad-spectrum clinical manifestations associated with 132 multi-organ involvement in patients infected with SARS-CoV-2, the main acute complications are scientifically well-delineated; however, late outcomes are still 133 134 in the recognition phase [12]. Considering the potential medium- and long-term sequelae in COVID-19 survivors, several organizations, including the WHO and 135 136 the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) have joined forces in scientific protocols and in the development of 137 international recommendations to identify and define the severity of persistent 138 manifestations after ICU and/or outpatient hospitalization [13]. 139

The most common complaints reported in scientific literature after 140 141 COVID-19 are caused by physiological, immunological, and inflammatory changes in response to infection, either directly by the virus or indirectly by the 142 patient's immune response [14,15]. The main complaints were dyspnea and 143 persistent fatigue followed by acquired muscle weakness, pulmonary 144 dysfunction, intolerance to moderate efforts, myalgia and arthralgia, post-145 146 traumatic stress disorder (PTSD), anxiety, and depression, which justify the worsening of functional status and quality of life in these patients [11,12,16,17]. 147 148 The fact that the frequency and severity of post-disease symptoms are not 149 directly associated or are exclusive to patients in the risk group or who develop 150 the severe form makes it an urgent need to characterize risk predictors and the potential differences between post-intensive care syndrome and the assignment 151 152 of rehabilitation programs to minimize sequelae [18,19].

153 The scientific community and health professionals have discussed the challenge of rehabilitating these patients who present with an infinity of clinical 154 155 manifestations, considering that knowledge is an important variable in 156 formulating guidelines aimed at structuring the organization, clinical treatment, and pulmonary rehabilitation of these patients with a focus on the 157 158 implementation of preventive and therapeutic measures [20-22]. The American Thoracic Society and European Respiratory Society (ATS/ERS) task force 159 160 advocates the inclusion of COVID-19 survivors in a pulmonary rehabilitation program (PRP) lasting 6-8 weeks. The initial experience in China also indicates 161 that a 6-week program can improve lung function, guality of life variables, 162 anxiety, and depression [23,24]. 163

Pulmonary rehabilitation is defined as "a multidisciplinary intervention 164 165 based on personalized assessment and treatment, which includes exercise 166 training, education, and behavioral modification designed to improve the physical and psychological condition of people with respiratory disease" [25]. In 167 patients infected with COVID-19 with persistent symptoms and sequelae, 168 pulmonary rehabilitation mainly seeks to improve dyspnea, relieve anxiety and 169 170 depression, prevent and reduce complications and/or dysfunctions, reduce 171 morbidity and mortality, and improve health-related guality of life as much as possible [26,27]. 172

Aerobic exercises, training of the ventilatory muscles, and muscle strengthening of the lower and upper limbs should be progressively offered to patients so that they can gradually recover the level of physical activity observed before the onset of the disease and eventually return to normal activities of daily living (ADLs). The principle of personalization must be respected regardless of the type of intervention in a PRP, based on the specific dysfunction of each patient [28-30].

180 **Objectives**

To verify through a clinical, prospective, and consecutive study the effects of an outpatient and home pulmonary rehabilitation program on clinical symptoms, pulmonary function, physical activity level, functional status, autonomic activity, peripheral muscle strength, static and functional balance assessment, functional mobility, anxiety and depression, post-traumatic stress, quality of life, and survival of patients with pulmonary sequelae from COVID-19.

187

188 Materials and Methods

189 Study design

This study will be a cohort, parallel, two-arm multicentric study, to be carried out 190 191 in three clinical centers, with blind transversal and longitudinal evaluation, with 192 06 weeks of training and follow-up. This clinical trial was designed according to the recommendations of the CONSORT statement [31]. This study protocol has 193 been designed in accordance with the SPIRIT 2013 Guidelines [32]. Currently, 194 this clinical trial is recruiting patients. The schedule of enrollment, interventions. 195 196 and assessments according to the SPIRIT guidelines are shown in Figure 1. All procedures of the study adhere to the CONSORT guidelines and are 197 summarized in a flowchart (Figure 2). 198

Figure 1. Schedule of enrollment, interventions, and assessments from SPIRITguidelines.

Figure 2. Study flowchart in accordance with the CONSORT statement.

202

203 Study setting

The study will be conducted at the Pulmonary Rehabilitation Laboratory of the Evangelical University of Goiás, UniEVANGÉLICA. Recruitment will take place between July 2021 and December 2022 through social media and banners distributed in reference hospitals for the treatment of patients with COVID-19 in the city of Anapolis (GO), Brazil. The city of Anápolis, in the interior of the state of Goiás, in the Midwest region of Brazil, is considered a center of reference in health in the region, receiving patients from several surrounding municipalities. 211 Many patients who seek care in the city come from neighboring cities and 212 therefore do not have an assistance service in the field of pulmonary 213 rehabilitation, and international biosafety standards for protection against 214 COVID-19 will be observed.

215 Ethical considerations and consent to participate

All procedures performed with the patients involved in this study were in 216 accordance with the international ethical standards for research involving 217 human. The research protocol was approved by the Ethics Committee for 218 219 Research with Human Beings of Universidade Evangélica de Goiás (UNIEVANGÉLICA) on September 24, 2020, under protocol number 4,235,203. 220 This clinical trial was registered at ClinicalTrials.gov (ID: COVID-19 221 222 PULMONARY REHAB NCT04982042). Involvement in the study will be voluntary, and leave will be allowed at any time without any burden. Participants 223 will be required to sign an informed consent form after receiving all information 224 about the pulmonary rehabilitation program. 225

226 Participants: recruitment and eligibility criteria

To be involved in this clinical study, according to the inclusion criteria, women and men aged between 16 and 75 years affected by COVID-19 will be invited.

229 Inclusion criteria

230 The following are the inclusion criteria:

231 Age 16–75 years

232 Patients who have been affected by COVID-19 and with impaired lung function

233 Clinically stabilized patients

- 234 Patients who agreed to participate in the pulmonary rehabilitation program for at
- least 12 weeks and signed a free and informed consent form
- 236 Exclusion criteria
- 237 The following are the exclusion criteria:
- 238 Hospitalized patients
- 239 Patients affected with chronic neurological diseases that make it impossible to
- 240 understand and perform physical activities
- 241 Patients suffering from hypertension and cardiovascular conditions without
- 242 medical treatment
- 243 Patients affected with acute phase of rheumatologic disorders
- 244 Patients who have recent musculoskeletal disorders and who are not fully
- 245 recovered from their injuries
- 246 Patients affected with chronic mental and/or psychological disturbances
- 247 Presence of terminal neoplastic disease
- 248 Red flags for serious conditions (night pain, severe muscle spasm, loss of
- involuntary weight, and symptom mismatch)
- Patients classified as severe cases according to the following criteria will alsobe excluded.
- Respiratory rate \geq 30 rpm
- SpO2 < 90%

254	•	Cardiac rate > 125 bpm
255	•	Hypotension (systolic blood pressure < 90 mmHg or diastolic blood
256		pressure < 60 mmHg)
257	٠	Severe dyspnea (minimal effort or rest)
258	•	Hemoptysis
259	•	Altered alertness (lethargy, acute confusion, disorientation)
260	•	Inability to consume orally due to unintended vomiting or a significant
261		number of bowel movements (≥ 10 per day), suggesting dehydration or
262		hydroelectric disturbances
263	٠	Significant impact on general health condition
264	•	A high clinical suspicion of pneumonia requiring radiography, based on
265		worsening of dyspnea, more than 7 days with fever, respiratory rate
266		higher than 22 rpm, and alteration in auscultation findings.

267 Interventions

Initially, all patients who met the inclusion criteria underwent clinical, physical, and psychological evaluations. They will then perform pulmonary function tests [33], peripheral muscle strength tests [34], and the 6-min walk test (6 MWT), in accordance with the standards recommended by the ATS [35]. The modified dyspnea scale of the Modified Medical Research Council [36] and the scales for anxiety and depression [37] will also be applied.

The proposed outpatient PRP is based on the guidelines recommended by the Brazilian Society of Pulmonology [38] and by the Global Initiative for Chronic Obstructive Lung Disease [39]. The Outpatient Pulmonary Rehabilitation Program consists of a combination of aerobic and muscle strengthening

exercises, lasting six weeks, with a frequency of three times a week, every 278 279 morning, according Table1. The pulmonary rehabilitation program consists of warm-up, training, and cool-down phases. The warm-up phase consisted of 280 281 intercalated calisthenic exercises for the muscle groups of the lower and upper limbs according to each patient's tolerance. The aerobic training phase is 282 performed on a treadmill or bicycle according to the patient's preference. During 283 284 the cooling-down phase, muscle stretching, and relaxation exercises are performed in a calm and silent environment. 285

Table 1. Combined aerobic exercise and muscle strengthening exercisestraining periodization.

	Outpatient PRP		Home PRP		
	Week 1-3	Week 4-6	Week 1-3	Week 4-6	
	Sets x	Sets x	Sets x	Sets x	
	Repetitions	Repetitions	Repetitions	Repetitions	
Aerobic exercise					
Bicycle/treadmill or					
walking					
Volume	30 minutes	40 minutes	30 minutes	40 minutes	
Intonsity % HP 6MW/T	60-70%	70-80%	50-60%	60-70%	
	(4-5 RPE)	(5-6 RPE)	(4-5 RPE)	(5-6 RPE)	
Muscle strengthening					
exercises					
Upper limb					
Upper limb diagonal	3 x 10-12	3 x 13-15	3 x 10-12	3 v 13-15	
(D1, adapted kabat)	5 10 12	0 × 10 10	0 1 10 12	5 × 15-15	
Upper limb diagonal	3 x 10-12	3 x 13-15	3 x 10-12	3 x 13-15	
(D2, adapted kabat)	0 1 10 12		0 1 10 12		
Lower limb					

Hip flexors with	2 x 10 12	2 × 12 15	2 x 10 12	2 x 12 15	
extended knee	3 X 10-12	3 X 13-15	3 X 10-12	5 X 13-15	
knee extenders	3 x 10-12	3 x 13-15	3 x 10-12	3 x 13-15	
knee flexors	3 x 10-12	3 x 13-15	3 x 10-12	3 x 13-15	
plantar flexors	3 x 10-12	3 x 13-15	3 x 10-12	3 x 13-15	
Volume	20 minutes	30 minutes	20 minutes	30 minutes	
Intensity 0/ 1PM	50-60%	60-70%	50-60%	60-70%	
	(4-5 RPE)	(5-6 RPE)	(4-5 RPE)	(5-6 RPE)	

289 PRP: Pulmonary Rehabilitation Program; HR heart rate; 6MWT: Six Minute
290 Walk Test; RPE: rating of perceived exertion; 1RM: one repetition maximum
291 test;

292 Home PRP

293 Home PRP will consist of the same combination of warm-up, strengthening, training, and relaxation exercises as the outpatient PRP. Initially, patients in this 294 295 group will receive exercise program training by a specialized healthcare professional on the research team and will be encouraged to follow the protocol 296 at home. The aerobic conditioning of this group will be performed by walking on 297 298 a flat terrain for up to 20 min, with an intensity of 60% to 80% of the maximum 299 heart rate reached in the 6 MWT, respecting individual tolerance and selfmonitoring throughout the training. You will be asked to complete a diary for 300 301 each training session. During the 6 weeks of training, individuals will receive weekly phone calls from the same researcher on the team to monitor the load 302 increase, detect any type of problem, clarify possible doubts, and reinforce the 303 importance of rehabilitation. Patients will be recommended to decrease the 304 intensity or discontinue the exercise in case of a high degree of dyspnea or any 305 306 other symptom of discomfort. The criteria for load increment in the upper- and lower-limb exercises will be the same as those for the outpatient group. 307

Upon completing 6 weeks of activities in the pulmonary rehabilitation program, patients will be recruited for a new evaluation, discharged, and encouraged to continue physical activities inherent to PRP at home. Each month, a new telephone contact will be made by a blinded evaluator asking about the general health status, adverse effects, and guidance regarding the continuity of physical activities.

Outcomes and measurements

All data regarding the initial and final evaluations after 6 weeks of training will be 315 316 collected by two physiotherapist researchers from the team. The collected data will be registered in standard forms for each outcome and then entered into an 317 Excel database for further analysis. Pulmonary function tests will be performed 318 319 by a technician trained in pulmonary function and interpreted by a pulmonologist. Physical therapists will perform muscle strength and exercise 320 capacity tests. Quality of life questionnaires and anxiety, depression, and stress 321 scales will be administered by an expert psychologist. All physical activities in 322 the PRP will be monitored by two physiotherapists, who will continuously check 323 324 the patients' vital signs. Below, we present the outcomes that will be evaluated 325 in the baseline evaluation and after 6 weeks of participation in the program. The 326 outcomes, measures, and assessment methods adopted in this clinical trial are shown in Table 2. 327

Table 2. Outcomes, measures, and assessment methods that will be used inthis clinical trial.

OUTCOMES	MEASURES	ASSESSMENT		
		t1	t2	
Pulmonary Function (FVC, VEF ₁ ,	Spirometry test	Х	Х	

VEF ₁ / FVC)			
Exercise Capacity	6MWT	Х	Х
Status Funcional	Post-COVID-19 Functional Status	\sim	v
	Scale	Λ	
Severity of Dyspnea	MRC Dyspnea Scale	Х	Х
Data on physical and, psychosocial	ISARIC Global Tier 1 COVID-19		
health and pre-COVID-19 baseline	Follow Up Survey. v1.2 21 Jan.	Х	Х
data	2021		
Maximal Inspiratory Pressure	POWERbreath	Х	Х
Sympathetic and Parasympathetic	Heart Rate Variability Analyses	Y	Y
Autonomic Activity		Λ	
Perinheral Muscle Strength	Handgrip dynamometer	Х	Х
r enpheral muscle Strength	MRC-SS	Х	Х
Static Balance Assessment	Force Platform	Х	Х
Functional Balance Assessment	Berg Balance Scale	Х	Х
Functional Mobility	TUG test	Х	Х
Muscle Fatigue	FSS	Х	Х
Quality of Life	SF-36 Questionnaire	Х	Х
	EQ-5D-5L	Х	Х
Anxiety and Depression Levels	HADS	Х	Х
Anniely and Depression Levels	SAS/SDS	Х	Х
Posttraumatic Stress Disorder	IES-6	Х	Х

t1: before intervention; t2: after intervention; FVC: Forced vital capacity; VEF₁: 330 Forced expiratory volume in one second; 6MWT: Six Minute Walk Test; mMRC: 331 modified Medical Research Council; ISARIC: International Severe Acute 332 Respiratory and emerging Infection Consortium; MRC-SS: Medical Research 333 Council Sum-Score; TUG: Timed Up and Go; FSS: Fatigue Severity Scale; SF-334 36: Short Form-36; EQ-5D-5L: EuroQol five dimension five levels; HADS: 335 Hospital Anxiety and Depression Scale; SAS/SDS: The Self-Assessment of 336 Anxiety Scale and the Self-Assessment of Depression Scale; IES-6: Event 337 Impact Scale - 6. 338

340 **Primary outcome**

341 **Pulmonary function: spirometry test**

The Koko Sx 1000 spirometer (Koko PFT, Fordham, Longmont, CO, USA) will 342 343 be used according the guidelines of the ERS, ATS [40, 41], and Brazilian Society of Pneumology [42]. Spirometry tests will be performed on all patients in 344 the morning after two puffs of salbutamol (400 µg), which will be administered 345 using a spacer (Volumatic, Glaxo Smith Kline LTD, London, UK). The best 346 forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) 347 348 were chosen for all analyses, regardless of the best curve. The ATS/ERS acceptability criteria for spirometry will be applied, including a minimum of three 349 respiratory maneuvers with at least two being free from artifacts. 350

351 Exercise capacity: walk test (6 MWT)

According to the guidelines published by the ATS (2002), the 6 MWT evaluates the distance a patient can walk quickly for a maximum period of 6 MWD. This test assesses the global and integrated responses of all systems involved in physical activities. [43] The 6 MWT is a simple, reliable, practical, low-cost, safe, and easy-to-apply functional capacity measure that can be performed in a flat, rigid space of 30 m. [44-46]

The test has been widely used to assess the functional status of patients with cardiorespiratory impairment and is highly correlated with morbidity and mortality [47-51]. An interesting review concluded that the 6 MWT is easy to administer, better tolerated, and more representative of ADLs than other walking tests [52].

363

364 Status Functional status: Post COVID-19 Functional Status Scale (PCFS)

Due to the wide variety of clinical symptoms and sequelae presented by 365 patients after COVID-19, it is of great importance to have a simple and 366 reproducible tool to assess the impact of the disease, monitor its evolution, and 367 guide rehabilitation actions [53,54]. Given the high incidence of pulmonary 368 embolism with myocardial damage/myocarditis and neurological complications 369 in patients with critical-stage COVID-19, Dr. Klok et al. proposed the use of the 370 371 PVFS scale (with a small adaptation) in the evaluation of patients after COVID-19. The authors suggest the use of the PVFS scale at hospital discharge, 4 and 372 373 8 weeks after discharge, and 6 months to assess the recovery of these patients. They also recognized that this instrument should not replace other established 374 and validated instruments in the assessment of quality of life, tiredness, or 375 376 dyspnea but could also be used as a tool for evaluating the results of the 377 functional state of intervention actions after COVID-19 [55,56].

This instrument covers functional level, limitations in daily life tasks, and lifestyle 378 379 changes at six levels. Level 0 demonstrates the absence of any functional 380 limitation, and the death of a patient is recorded in grade D. From level 1 onwards, symptoms, pain, or anxiety are presented in ascending order. This 381 382 had no effect on the activities of patients in grade 1, whereas a lower intensity 383 of activities was required for those in grade 2. Level 3 is characterized by the 384 inability to perform certain activities, forcing patients to adapt. Finally, level 4 is reserved for patients with severe functional limitations who need assistance in 385 386 performing ADLs [57, 58].

387

388 Severity of dyspnea: Medical Research Council (MRC) Dyspnea Scale

In patients with chronic obstructive pulmonary disease (COPD), it has been 389 observed that the interaction between dyspnea, physical deconditioning, and 390 muscle weakness results in a vicious circle or negative spiral [59], which 391 392 generates important functional limitations [60]. In real life, these functional limitations are characterized by a reduction in the ability to perform ADLs [61]. It 393 has been observed that a close relationship exists between physical ADL, 394 395 morbidity, and mortality in patients with COPD, calling attention to the adequate 396 evaluation and follow-up of their evolution [62-64]. In this study, owing to its ease of application and understanding, the MRC scale will be used, an 397 instrument traditionally used in the international literature [65,66]. 398

The MRC scale consists of five items, where the patient defines the item that best corresponds to the extent to which dyspnea limits daily activities. The patient reported his subjective degree of dyspnea, choosing a value between 1 (shortness of breath only during intense exercise) and 5 (shortness of breath when getting dressed or feeling short of breath that he no longer leaves the house) [67,68].

405 Secondary outcome

406 Physical and psychosocial health COVID-19: International Severe Acute 407 Respiratory and Emerging Infections Consortium (ISARIC)

ISARIC has recently published the COVID-19 response timeline to mark the amazing work performed by all those using ISARIC's resources and clinical data platform since the beginning of the pandemic; the timeline showcases how the federation has taken action right from the start of the pandemic to address

the most important research questions to further the knowledge of COVID-19,

thereby saving lives and providing a collaborative platform through which global,

414 patient-oriented clinical studies can be developed, executed, and shared.

Protocols addressing the most important questions between and during epidemics of severe acute respiratory infections and other rapidly emerging public health threats are undertaken to generate new knowledge, maximize the availability of clinical information, and thereby save lives.

The ISARIC COVID-19 follow-up protocol was based on the ISARIC/WHO COVID-19 Clinical Characterization Protocol. It assesses the risk and risk factors for long-term physical and psychosocial health consequences following COVID-19 diagnosis using a range of validated tools. This protocol will followup patients with confirmed COVID-19 using standardized data collection forms.

The forms can be completed as patient self-assessment via post or an online link, or via clinician/research-led completion via telephone or in-clinic. It can be used to identify people for further in-clinic follow-up and assessment or in conjunction with sampling and diagnostic studies.

Assessment of the risk factors for long-term sequelae requires data on pre-428 429 existing conditions and care received during the acute phase of the disease. In this way, ISARIC created tools for researchers to collect and store clinical data 430 431 in a standardized manner through COVID-19 follow-up surveys. The Tier 1 Initial Follow-up Survey will be used in the initial assessment of patients, and 432 the Tier 1 Ongoing Follow-up Survey will be used in the reassessment after six 433 weeks of intervention. The original versions were made available in English and 434 were later translated into other languages, including Portuguese [69,70]. 435

This is an open-access tool that collects data on physical and 436 437 psychosocial health, occupational status, and socioeconomic variables, as well as pre-COVID-19 baseline data that make it possible to characterize the 438 physical and psychosocial repercussions after hospital discharge and/or sharp. 439 440 These include vaccination data, hospitalization and possible decompensations and/or readmissions, specific consequences including deep vein thrombosis 441 442 (DVT), stroke or transient ischemic attack, pulmonary embolism, recent febrile illness, new or persistent symptoms, quality of life (assessed using the EQ-5D-443 5L and EQ VAS), dyspnea (measured by the MRC dyspnea scale), difficulties in 444 445 ADLs due to health problems (UN/Washington disability score), and lifestyle 446 [71].

447 Maximal inspiratory pressure (MIP): POWERbreath

The pressure generated by the inspiratory muscles will be quantified 448 using an electronic threshold device (PowerBreathe Medic KH2, IMT 449 Technologies Ltd., Birmingham, UK). It features an advanced live feedback 450 software (Breathe-Link Medic), which allows patient results to be viewed in real 451 452 time. To measure the MIP, patients should be comfortably seated, encouraged to perform a maximal expiratory effort from the residual volume, and then a 453 454 verbal command will be given to perform a maximal inspiratory effort, according 455 to ATS/ERS standards [72]. The reference values used were described by Pessoa et al. (2014), based on parameters for the Brazilian population [73]. 456

457 Nervous autonomic activity: heart rate variability (HRV) analyses

458 HRV was analyzed using Kubios HRV software (Kubios Ou Limited company,
459 Kuopio, Finland). This software is widely known and is used worldwide with

different patient populations and healthy individuals. It is a well-developed, 460 461 validated, and easy-to-use software for analyzing the behavior of sympathetic and parasympathetic autonomic activities. This software is considered to be the 462 gold standard for HRV analysis. In this clinical research protocol, HRV analysis 463 464 will be performed during the 6 MWT. Data will be collected using the Kubios software from the heart rate and time, obtaining the time values referring to the 465 R-R intervals. Five minutes will be collected with the patient seated, at rest 466 before starting the test, during the 6 min of walking and for 5 min after the test, 467 and sitting at rest. HRV analyses will be performed in the time and frequency 468 469 domains, as well as in nonlinear models.

470 **Peripheral muscle strength**

471 Handgrip dynamometer

According to the recommendations of the American Society of Hand Therapists, 472 handgrip strength should be assessed using a dynamometer on both sides 473 474 (dominant and non-dominant). In this protocol, hand grip strength will be verified using the digital hand dynamometer Jamar® Plus Hand Dynamometer 475 (JAMAR® Hydraulic Hand Dynamometer, Sammons Preston, Bolingbrook, IL, 476 USA). Patients should be seated with their feet firmly on the floor, shoulders 477 adducted, elbows flexed at 90°, and forearms in a neutral position [74], and the 478 position of the equipment handle should be chosen by the patient himself [75]. 479 Three tests will be performed on each side, alternately, with a rest period of at 480 least 1 min between attempts on the same hand [76]. The highest value 481 observed in each upper limb was used to represent maximum handgrip strength 482 [77]. The dynamometer was adjusted according to the size of the hand of each 483

patient. After instruction, the participant pressed the dynamometer until
maximum strength was displayed, and the results were recorded in kilograms to
one decimal place [78].

487 MRC sum-score (MRC-SS)

The MRC-SS assesses the global peripheral muscle strength of six upper and lower limb muscle groups (shoulder abduction, elbow flexion, wrist extension, hip flexion, knee extension, and ankle dorsiflexion) on both sides, from 5 (normal strength) to 0 (no visible contraction). The sum of the scores ranges from 0 to 60, where scores below 48 indicate significant peripheral muscle weakness and scores below 36 indicate severe weakness. The therapist's hand placement and patient positioning were standardized [79].

Muscle strength will initially be evaluated against gravity, and the movements to be evaluated will be passively demonstrated. If the patient could not perform the movement, positioning was modified [80]. An isometric resistance was applied to the end of the range of motion to test each degree of muscle strength. This score has been widely used for the diagnosis of ICU-acquired weakness (ICU-AW) [81,82].

501 Functional balance assessment: Berg balance scale

The Berg balance scale assesses functional balance by performing 14 tasks of daily living, with a global score of 56 possible points. Items were scored from 0-4, with 0 representing the inability to complete the task and 4 representing the ability to complete the proposed task. A score from 0 to 20 represents impairment of balance, 21 to 40 represents acceptable balance, and 41 to 56 represents good balance [83].

508

509 Functional mobility: timed Up & Go (TUG)

The TUG test is an instrument that allows the assessment of functional mobility in different populations as a function of time [84,85]. To perform the test, the patient had to get up from a standardized chair, walk 3 m at a comfortable pace, return to the chair, and sit down. The test will be performed with the subjects on barefoot/shoes three times, the first time for familiarization. Time intervals above 16 s are indicate impairment of the patient's functional mobility and identified as a high fall risk [86].

517 TUG test data were obtained using a wireless inertial detection device: Inertial Sensor: G-Sensor® (BTS Bioengineering Corp., Quincy, MA, USA). A portable 518 Gsensor is a wireless inertial sensor system used to analyze human 519 movements. The sensors were controlled by a data logging unit (up to 16 520 521 elements) via ZigBee-type radio communication. Each sensor has dimensions of 62 mm x 36 mm x 16 mm, weighs 60 g, and is composed of a three-axis 522 accelerometer (maximum scale ± 6 g), a 3-axis gyroscope (full scale $\pm 300^{\circ}$ /s), 523 524 and a magnetometer 3-axis (full scale \pm 6 Gauss). This device was calibrated with gravitational acceleration immediately after manufacturing. For this study, 525 526 only one device was used to collect data at a sampling frequency of 50 Hz. The data from the inertial sensor were transmitted via Bluetooth to a computer and 527 processed using proprietary software (BTS GSTUDIO, version: 2.6.12.0), which 528 automatically provided the parameters. The TUG test has been validated in a 529 population of patients with COPD. 530

531

532 Static balance assessment: Force platform

Postural balance is assessed using stabilometry, also called oscillometry, which 533 measures oscillations in the standing posture. This condition is measured 534 through the displacement of the center of pressure (COP) while the individual 535 remains standing on the platform for a certain time [87]. It allows detection of 536 the slightest variations in amplitude and frequency of displacement of the body's 537 center of gravity, helping to analyze the functional aspects related to body 538 539 imbalance. It is a technique used to evaluate the plantar pressure exerted by the body, which allows the detection of postural oscillations and balance deficits 540 541 [88].

To assess static balance, the SMART-D 140® System (BTS Bioengineering 542 543 Corp., Quincy, MA, USA) containing two force platforms (Kistler Platform model 9286BA) was used. The platform acquisition frequency was 100 Hz, captured 544 by four piezoelectric sensors positioned at the extremities of the force platform 545 measuring 400/600 mm. Data were recorded and interpreted using SWAY BTS 546 161 Engineering software (BTS Bioengineering Corp., Quincy, MA, USA), 547 548 integrated, and synchronized with the SMART-D 140® system (BTS Bioengineering Corp., Quincy, MA, USA). The collection protocol to be 549 550 conducted includes the instruction to remain in a standing position, as still as possible, with the arms close to the body and the head kept in a vertical 551 552 position. Measurements (30 s) of the COP displacement on the X (anteriorposterior), Y (medium-lateral), and COP-GOG axes will be taken under the 553 554 conditions of eyes open and eyes closed, with the proprioceptive perturbation that configures as a soft surface collecting with open eyes and eyes closed. 555

556 Muscle fatigue: Fatigue Severity Scale (FSS)

557 The FSS is one of the most widely used fatigue self-assessment scales worldwide. This scale classifies the severity of a patient's fatigue symptoms in 558 559 terms of how they compromise their motivation, physical activity, and ADLs. The 560 scale is composed of a self-report questionnaire with nine items, with scores ranging from 1 to 7, where 1 indicates strongly disagree and 7 indicates strongly 561 agree [89,90]. The scale is scored by the total sum or by the calculation of an 562 563 average score on the nine items, with higher scores indicating more severe fatigue. A score \geq 4 indicated fatigue [91]. The FSS has been translated and 564 565 validated in several languages including Portuguese. Participants will be asked to respond to the FSS relative to the previous week [92]. 566

567 Health-related Quality of life

568 Short Form Health Survey 36 (SF-36) questionnaire

569 In this protocol, health-related quality of life is assessed using a generic 570 instrument. The SF-36 is a multidimensional questionnaire frequently used to assess the quality of life of patients. This instrument was developed by Ware 571 and Sherbourne [93] and validated in Brazil by Ciconelli et al. [94]. It consists of 572 36 questions that analyze eight health domains: functional capacity, limitations 573 574 due to physical aspects, pain, general health status, vitality, social aspects, 575 limitations due to social aspects, and mental health [95]. A final score ranging from 0 to 100 is generated from each domain, and the higher the score, the 576 better the health-related quality of life [96]. 577

578

579 **EuroQol five dimension five levels** (EQ-5D-5L)

The EQ-5D-5L version was introduced by the EuroQol Group in 2009 with the 580 aim of improving the instrument's reliability and sensitivity compared to the EQ-581 5D-3L. The EQ-5D-5L consists of the EQ-5D descriptive system, covering five 582 583 dimensions: mobility. self-care. usual activities. pain/discomfort, and anxiety/depression. Each dimension has five levels of severity: none, mild, 584 moderate, severe, and extreme. The patients will be asked to indicate their 585 586 health status in each of the five dimensions. A score can be calculated from the scores generated by each domain, with higher scores representing a better 587 quality of life [96-98]. 588

589 Anxiety and depression levels

590 The Hospital Anxiety and Depression Scale (HADS)

Several instruments in the scientific literature have been used to assess anxiety 591 and depression [99] The HADS was created 30 years ago by Zigmond and 592 Snaith to identify symptoms of anxiety and depression in non-psychiatric 593 594 inpatients and later on in outpatients and other types of patients [100]. The 595 HADS has been validated for use in Brazil by [101], and it is short and takes a few minutes to complete while waiting for an appointment with the doctor. The 596 597 HADS uses a 4-point response scale (0–3) according to the severity of anxiety and depression. The depression domain was measured using seven items, and 598 the other seven items measured the anxiety domain. The total score for each 599 domain ranges from 0 to 21. In both domains, cases with scores from 0 to 7 600 601 points were considered normal, cases from 8 to 10 points were considered to 602 have a borderline abnormality, and scores from 11 to 21 were evaluated as cases of anxiety or depression depending on the dotted domain.1. 603

The Self-Assessment of Anxiety Scale (SAS) and the Self-Assessment of Depression Scale (SDS)

The SAS and SDS are instruments commonly used in the assessment of negative emotions in clinical practice and are frequently applied to assess the state of adults with symptoms of anxiety and depression [102].

Each scale is composed of 20 items, using a four-level score formulated as 609 positive (1–4) or negative (4–1). The SAS identifies the presence of affective 610 symptoms based on diagnostic criteria corrected in the American psychiatric 611 612 literature and assesses four dimensions: cognitive, motor, vegetative, and 613 central nervous system. The total scale score was the sum of the scores for each item. A score below 50 indicates anxiety, a score of 50-60 indicates level 614 615 anxiety, a score of 61-70 indicates moderate anxiety, and a score above 70 indicates severe anxiety. 616

The choice of items on the SDS scale was based on studies of an analytical factor of depressive symptoms. The cutoff score was 53, indicating that standard scores greater than 53 induced depression [103]. In Brazil, there has already been validation for the SAS, which has been used with excellent reliability [104]. Both scores range from 20 to 80 (raw score), and then these scores are converted into indices ranging from 25 to 100.

623 Posttraumatic stress disorder: Impact of Event Scale-6 (IES-6)

The IES-6 is an abbreviated version of the Impact of Event Scale-Revised (IES-R), which consists of six five-point items, ranging from 0 to 4 [105]. The IES-6 is an instrument used to identify individuals with significant symptoms of traumatic stress who need a more extensive evaluation to determine the diagnostic criteria

for PTSD, without confirmation of a clinical diagnosis [106]. The IES-6 is a reliable and valid tool for screening PTSD and survivors of ARDS and is widely used in hospitalized and discharged patients [107]. This scale has been used in some studies to assess the prevalence of and risk factors for PTSD in patients with COVID19 [108].

633 Safety assessment

All patients will be monitored during all pulmonary rehabilitation program 634 635 activities. Vital signs, such as temperature, heart rate, partial oxygen saturation, and peripheral blood pressure, will be evaluated at the beginning, during, and at 636 the end of each session. Peripheral oxygen saturation and heart rate were 637 continuously monitored using a G-Tech pulse oximeter (Beijing Choice 638 Electronics Technology Co., Ltd., Beijing, China). Peripheral blood pressures 639 will be measured using a clinical Premium aneroid sphygmomanometer 640 (Wenzhou Instruments Co, China) at the beginning and end of the session or if 641 the patient shows any pressure discomfort. 642

The perceived exertion by the patients was registered throughout the aerobic 643 644 training phase using the Borg Dyspnea Scale. Training will always be 645 conducted by an experienced physiotherapist, who is a member of the research 646 team. If the systolic and/or diastolic blood pressure reaches the maximum pre-647 established limits, the patient will be instructed to reduce the effort and/or stop the activity for a few minutes until the pressure stabilizes and returns to normal 648 values. In view of this clinical situation, the patient was referred to a specialist 649 650 physician for clinical re-evaluation.

651

652 Sample size and power calculation

653 The sample size was calculated according to Shahin et al. (2008). This calculation is based on the mean difference in the distance covered in the test, 654 which should be clinically significant. Considering a difference within +8 655 656 (control) and +46 (intervention), for a sample size of 35 and 36 patients, respectively, and an SD within each group of 9.2, an α error probability of 0, 05, 657 and a power (1 - error probability β) of 0.80 for repeated measures, for repeated 658 659 measures analysis (between factors), a total sample size of 36 individuals was needed to reach a power of 81.77%. An additional 10% of subjects were 660 required to adjust for other factors, such as dropouts, lost data, and loss to 661 follow-up, which resulted in a total of 40 subjects per group. G*Power Statistical 662 Power Analyses for Mac were utilized according to the appropriate reference 663 664 [109,110].

665 Statistical analyses

666 The Kolmogorov–Smirnov test was used to test the normality of the distribution of the verified variables. For intragroup comparisons, we will use the Student's 667 t-test for paired samples that presented parametric distribution or the Mann-668 669 Whitney test for variables whose distribution was non-parametric. Intergroup comparisons were made using one-way analysis of variance (ANOVA), and 670 Tukey's post-test was used for paired comparisons whenever the null 671 672 hypothesis was rejected by ANOVA. For intergroup comparisons of variables that presented a non-parametric distribution, we used the Kruskal-Wallis test, 673 and the paired comparison (when the null hypothesis was rejected) was made 674 using the Mann-Whitney test. The chi-square test was used to test the 675

association between the groups and exacerbations/hospitalizations. All
analyses will be performed using the Statistical Package for Social Science
(SPSS) version 23.0 (IBM Corp. Released 2015. IBM SPSS Statistics for
Windows, version 23.0. Armonk, NY: IBM Corp). The significance level
established for all analyses was set at 5%.

681 Data management

682 All clinical data of the patients involved in the study will be collected through specific standardized forms for clinical evaluation and stored in a database 683 684 created by the Scientific Coordination of the Protocol and protected by a password. All patient identification will be replaced by a code to maintain the 685 confidentiality of the data collected. At the end of each activity day, the collected 686 687 data were backed and exported to another computer. Any changes to the proposed protocol will be immediately communicated to the institution's 688 Research Ethics Committee and ClinicalTrials.gov. 689

690 Strategies of study retention

In the initial phase of protocol evaluation, all patients will participate in a health 691 692 education program at the institution, where they will receive information about the development and progression of the disease, its treatment (both drug and 693 694 non-drug), the correct use of oxygen, and the importance of participating in a pulmonary rehabilitation program. All patients received a booklet containing the 695 696 content of the educational program and guidance on the practice of physical activities. During the study period, participants allocated to the home pulmonary 697 rehabilitation group will receive weekly phone calls to monitor the activities 698 performed during the week, check for the presence of adverse events, and 699

encourage and not drop out of the program. Psychological strategies to improve
self-esteem will also be adopted by all patients and their caregivers.

702 **Discussion**

703 International scientific literature has demonstrated the effectiveness of 704 pulmonary rehabilitation in patients with chronic and acute lung diseases. In this sense, we hope that patients affected by COVID-19 undergoing an outpatient 705 706 and home pulmonary rehabilitation program will obtain benefits in the short. medium-, and long-term. We highlight the benefits in terms of reduced fatigue 707 708 and dyspnea, increased functional and exercise capacity, reduced limitations in ADLs, improved guality of life, mood and motivation, increased adherence to 709 recommended clinical treatments, increased participation in therapy decisions, 710 711 strengthening the patient's self-management capacity, and reducing the amount 712 of health care for patients, families, and communities, including reducing the number of hospitalizations and increasing survival, with a consequent reduction 713 in health costs for the state. 714

715 **Potential impact and significance of the study**

According to the international scientific literature, which shows excellent results 716 of pulmonary rehabilitation for patients with pulmonary diseases, we expect 717 718 that, with the participation of patients affected by COVID-19 in outpatient and home pulmonary rehabilitation programs, we will obtain benefits in the short, 719 medium, and long term. The potential clinical impact of this study will be to 720 721 reduce fatigue and dyspnea, increase functional and exercise capacity, reduce 722 limitations in ADLs, improve quality of life, and consequently reduce morbidity and mortality in patients affected by COVID-19. A reduction in decompensation 723

and hospitalizations is also expected, representing a reduction in health costs by the government. It is hoped that with the results of this clinical trial, we can encourage the scientific community to increase the availability of pulmonary rehabilitation programs for the large number of patients surviving COVID-19, improve the quality of life, and increase survival.

729 Strengths and weakness of the study

730 Currently, there are a small number of clinical trial protocols for pulmonary rehabilitation programs aimed at patients with post-COVID-19 sequelae 731 732 according to international clinical trial registry agencies. A strong point of the research is that patients who cannot access the activities of the outpatient 733 pulmonary rehabilitation program will be able to perform the same activities at 734 735 home. Another strength of this clinical trial is that robust results were not observed in the scientific literature on the clinical response of post-COVID-19 736 patients undergoing pulmonary rehabilitation programs. One weakness of this 737 clinical trial is the fact that it is not controlled; however, it is justified by the fact 738 739 that it is unethical to leave patients who present sequelae of COVID-19 without 740 participating in a rehabilitation program.

741 **Dissemination policy**

The results of this clinical trial will be shared with potential users and peers in the field of research, scientific societies, and people formulating public health policies, thus contributing to the progress of science in general and improving the population's quality of life. The results of this study will be presented at scientific conferences and submitted as a manuscript to scientific journals. The database is made available upon request.

748 How amendments to the study, including termination, will be dealt with

Any changes in the execution of the proposed initial protocol and/or adverse events that occur to patients will be communicated to the Research Ethics Committee of the institution, ClinicalTrials.gov, and the health authorities of our country.

753 Acknowledgements

The authors would like to thank Fundação de Amparo a Pesquisa do Estado de

755 Goiás (FAPEG) and Universidade Evangélica de Goiás (UniEVANGÉLICA) for

their support in all phases of organizing this study protocol.

757

- 758
- 759

760 **References**

761	1.	Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic.
762		Acta Biomed. 2020;91(1):157-160.
763	2.	Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E,
764		Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, et al.
765		Clinical, laboratory and imaging features of COVID-19: A
766		systematic review and meta-analysis. Travel Med Infect Dis.
767		2020;101623.
768	3.	Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli
769		A, et al. Baseline Characteristics and Outcomes of 1591 Patients
770		Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy
771		Region, Italy. JAMA. 2020;323(16):1574-1581.

....

.....

~ ~

7724.Wu Z, McGoogan JM. Characteristics of and Important Lessons773From the Coronavirus Disease 2019 (COVID-19) Outbreak in774China: Summary of a Report of 72 314 Cases From the Chinese

775 Center for Disease Control and Prevention. JAMA. 2020;776 323(13):1239-1242.

- 7775.Cheng ZJ, Shan J. Review 2019 Novel coronavirus: where we are778and what we know. Infection. 2020;48(2):155-163.
- 6. WHO. Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19) WHO; 2020. Feb 16-24, [accessed on 2022 mar 8]. Available at: https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf.
- 784
 7. Kakodkar P, Kaka N, Baig M. A comprehensive literature review
 785
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 787
 786
 786
 786
 787
 786
 786
 786
 786
 786
 786
 786
 787
 786
 786
 786
 786
 787
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
 786
- Epidemiology Working Group for NCIP Epidemic Response,
 Chinese Center for Disease Control and Prevention. [The
 epidemiological characteristics of an outbreak of 2019 novel
 coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing
 Bing Xue Za Zhi. 2020;41(2):145-151.
- 9. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T,
 Davidson KW. Presenting characteristics, comorbidities, and
 outcomes among 5700 patients hospitalized with COVID-19 in the
 New York city area. J. Am. Med. Assoc. 2020;323(20):2052–2059.
- 79610.Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and797risk factors for mortality of adult inpatients with COVID-19 in798Wuhan, China: a retrospective cohort study. Lancet.7992020;395(10229):1054-1062.
- 800 11. Sanchez-Ramirez DC, Normand K, Zhaoyun Y, Torres-Castro R.
 801 Long-term impact of COVID-19: A systematic review of the
 802 literature and meta-analysis. Biomedicines. 2021;9(8),900.
- Salamanna F, Veronesi F, Martini L, Landini MP, Fini M. PostCOVID-19 Syndrome: The Persistent Symptoms at the Post-viral
 Stage of the Disease. A Systematic Review of the Current Data.
 Front Med (Lausanne). 2021;8:653516.
- 80713.Sigfrid L, Cevik M, Jesudason E, Lim WS, Rello J, Amuasi J, et al.808What is the recovery rate and risk of long-term consequences

809following a diagnosis of COVID-19? A harmonised, global810longitudinal observational study protocol. BMJ Open.8112021;11(3):e043887.

- Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of
 SARS-CoV-2 infection–a review of immune changes in patients
 with viral pneumonia. Emerg Microbes Infect. 2020;9:727–32.
- 15. Darif D, Hammi I, Kihel A, El Idrissi Saik I, Guessous F, Akarid K.
 The pro-inflammatory cytokines in COVID-19 pathogenesis: What
 goes wrong? Microb Pathog. 2021;153:104799.
- 81816.Jennings G, Monaghan A, Xue F, Mockler D, Romero-Ortuño R. A819Systematic Review of Persistent Symptoms and Residual820Abnormal Functioning following Acute COVID-19: Ongoing821Symptomatic Phase vs. Post-COVID-19 Syndrome. J Clin Med.8222021;10(24):5913.
- Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R,
 Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of
 COVID-19: a systematic review and meta-analysis. Scientific
 reports.2021;11(1), 1-12.
- Nakanishi N, Liu K, Kawakami D, Kawai Y, Morisawa T, Nishida T, 18. 827 et al. Post-Intensive Care Syndrome and Its New Challenges in 828 Coronavirus Disease 2019 (COVID-19) Pandemic: A Review of 829 Advances Perspectives. J Clin 830 Recent and Med. 831 2021:10(17):3870.
- 19. Cabrera Martimbianco AL, Pacheco RL, Bagattini ÂM, Riera R.
 Frequency, signs and symptoms, and criteria adopted for long
 COVID-19: A systematic review. International journal of clinical
 practice. 2021;75(10)e14357.
- Vitacca M, Lazzeri M, Guffanti E, Frigerio P, Gianola S, Carone M,
 et al. An Italian consensus on pulmonary rehabilitation in COVID19 patients recovering from acute respiratory failure: results of a
 Delphi process. Monaldi Archives for Chest Disease. 2020;90(2).
- 84021.Barker-Davies RM, O'Sullivan O, Senaratne KPP, Baker P,841Cranley M, Dharm-Datta S, et al. The Stanford Hall consensus

statement for post-COVID-19 rehabilitation. Br J Sports Med.
2020;54(16):949-959.

- Spruit MA, Holland AE, Singh SJ, Tonia T, Wilson KC, Troosters
 T. COVID-19: Interim Guidance on Rehabilitation in the Hospital
 and Post-Hospital Phase from a European Respiratory Society
 and American Thoracic Society-coordinated International Task
 Force. Eur Respir J. 2020.
- Zhao HM, Xie YX, Wang C. Chinese Association of Rehabilitation 849 23. Medicine: Respiratory Recommendations for respiratory 850 851 rehabilitation in adults with coronavirus disease 2019. 852 Rehabilitation Committee of Chinese Association of Rehabilitation Medicine: Cardiopulmonary Rehabilitation Group of Chinese 853 854 Society of Physical Medicine and Rehabilitation. Chin Med J (Engl). 2020;133(13):1595-1602. 855
- Bai C, Chotirmall SH, Rello J, Alba GA, Ginns LC, Krishnan JA, et
 al. Updated guidance on the management of COVID-19: from an
 American Thoracic Society/European Respiratory Society
 coordinated International Task Force (29 July 2020). Eur Respir
 Rev. 2020;29(157):200287.
- 25. Spruit MA, Singh SJ, Garvey C, ZuWallack R, Nici L, Rochester C, 861 et al. ATS/ERS Task Force on Pulmonary Rehabilitation. An 862 official American Thoracic Society/European Respiratory Society 863 864 statement: kev concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013;188(8):e13-64. 865
- 866 26. Gloeckl R, Leitl D, Jarosch I, Schneeberger T, Nell C, Stenzel N,
 867 et al. Benefits of pulmonary rehabilitation in COVID-19: a
 868 prospective observational cohort study. ERJ Open Res.
 869 2021;7(2):00108-2021.
- 870 27. Everaerts S, Heyns A, Langer D, Beyens H, Hermans G,
 871 Troosters T, et al. COVID-19 recovery: benefits of multidisciplinary
 872 respiratory rehabilitation. BMJ Open Respir Res.
 873 2021;8(1):e000837.
- 87428.Mohamed AA, Alawna M. Role of increasing the aerobic capacity875on improving the function of immune and respiratory systems in

patients with coronavirus (COVID-19): a review. Diabetes Metab
Syndr 2020;14:489–496.

- 878 29. Santana AV, Fontana AD, Pitta F. Pulmonary rehabilitation after
 879 COVID-19. J Bras Pneumol. 2021;47(1):e20210034.
- 30. Wang TJ, Chau B, Lui M, Lam GT, Lin N, Humbert S. PM&R and
 pulmonary rehabilitation for COVID-19. American journal of
 physical medicine & rehabilitation. 2020.
- Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT
 2010 statement: updated guidelines for reporting parallel group
 randomized trials. Ann Intern Med. 2010;152(11):726-32.
- 32. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC,
 Krleža-Jerić K, et al. SPIRIT 2013 statement: defining standard
 protocol items for clinical trials. Ann Intern Med. 2013;158(3):2007.
- 33. American Thoracic Society Statement. Lung function testing:
 selection of reference values and interpretative strategies. Am Rev
 Respir Dis.1991;144:1202-18.
- 34. Medina-Mirapeix F, Bernabeu-Mora R, Llamazares-Herrán E,
 Sánchez-Martínez MP, García-Vidal JA, Escolar-Reina P.
 Interobserver Reliability of Peripheral Muscle Strength Tests and
 Short Physical Performance Battery in Patients With Chronic
 Obstructive Pulmonary Disease: A Prospective Observational
 Study. Arch Phys Med Rehabil. 2016;97(11):2002-2005.
- 35. ATS Committee on Proficiency Standards for Clinical Pulmonary
 Function Laboratories. ATS statement: guidelines for the sixminute walk test. Am J Respir Crit Care Med. 2002;166:111-7.
- 90236.Wedzicha JA, Jones PW. Usefullness of the Medical Research903Council (MRC) dyspnea scale as a measure of disability in904patients with chronic obstructive pulmonary disease.
- 37. Saidi I, Koumeka PP, Ait Batahar S, Amro L. Factors associated
 with anxiety and depression among patients with Covid-19. Respir
 Med. 2021 Sep;186:106512.
- 90838.Sociedade Brasileira de Pneumologia e Tisiologia. I Consenso909brasileiro sobre espirometria. J Pneumol. 1996;22:105-164.

910 39. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS;
911 GOLD Scientific Committee. Global strategy for the diagnosis,
912 management, and prevention of chronic obstructive pulmonary
913 disease. NHLBI/WHO Global Initiative for Chronic Obstructive
914 Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care
915 Med. 2001;163(5):1256-76.

- 91640.Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R,917Coates A, et al. ATS/ERS Task Force. Standardisation of918spirometry. Eur Respir J. 2005;26(2):319-38.
- 919 41. Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper
 920 BG, Hall GL, et al. Standardization of Spirometry 2019 Update. An
 921 Official American Thoracic Society and European Respiratory
 922 Society Technical Statement. American Journal of Respiratory and
 923 Critical Care Medicine. 2019; 200(8):e70–e88.
- 924 42. Pereira CAC. Il Consenso Brasileiro de Espirometria. J Pneumol
 925 2002;28(3):S1-S82.
- 43. ATS Committee on Proficiency Standards for Clinical Pulmonary
 Function Laboratories. ATS statement: guidelines for the sixminute walk test. Am J Respir Crit Care Med. 2002;166(1):111117.
- 93044.Sciurba FC, Slivka WA. Six-minute walk-testing. Semin Resp Crit931Care Med 1998; 9: 383–391.
- 93245.ATS Statement: Guidelines for the six-minute walk test. Am J933Respir Crit Care Med 2002; 166: 111–117.
- 934 46. Enright PL, McBurnie MA, Bittner V, Tracy RP, McNamara R,
 935 Arnold A, Newman AB; Cardiovascular Health Study. The 6-min
 936 walk test: a quick measure of functional status in elderly adults.
 937 Chest. 2003;123(2):387-98.
- 938 47. Casanova C, Cote C, de Torres JP, et al. The inspiratory lung
 939 capacity ratio predicts mortality in patients with COPD. Am J
 940 Respir Crit Care Med 2005; 171: 591–597.
- 941 48. Pitta F, Troosters T, Spruit MA, et al. Characteristics of physical
 942 activities in daily life in COPD. Am J Respir Crit Care Med 2005;
 943 171:972–977.

- 944 49. Pinto-Plata VM, Cote C, Cabral H, et al. The 6-min walk distance:
 945 change over time and value as a predictor of survival in severe
 946 COPD. Eur Respir J 2004; 23: 28–33.
- 50. Casanova C, Cote C, Marı'n JM, et al. Distance and oxygen
 desaturation during six minute walk test as predictors of longterm
 mortality in patients with COPD. Chest 2008; 134: 746–752.
- 51. Cote CG, Casanova C, Marı'n JM, et al. Validation and
 comparison of reference equations for the six-minute walk test.
 Eur Respir J 2008; 31: 571–578.
- 52. Solway S, Brooks D, Lacasse Y, Thomas S. A qualitative
 systematic overview of the measurement properties of functional
 walk tests used in the cardiorespiratory domain. Chest
 2001;119:256–270.
- 53. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers
 D, Kant KM, et al. Confrmation of the high cumulative incidence of
 thrombotic complications in critically ill ICU patients with COVID19: an updated analysis. Thromb Res. 2020;191:148–50.
- 961 54. Klok FA, Barco S, Siegerink B. Measuring functional limitations
 962 after venous thromboembolism: a call to action. Thromb Res.
 963 2019;178:59–62.
- 55. Boon GJAM, Barco S, Bertoletti L, Ghanima W, Huisman MV,
 Kahn SR, et al. Measuring functional limitations after venous
 thromboembolism: optimization of the Post-VTE Functional Status
 (PVFS) Scale. Thromb Res. 2020;190:45–51.
- 56. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers
 D, Kant KM, et al. Confirmation of the high cumulative incidence of
 thrombotic complications in critically ill ICU patients with COVID19: an updated analysis. Thromb Res. 2020;191:148–50.
- 97257.Klok FA, Boon GJ, Barco S, Endres M, Geelhoed JM, Knauss S,973et al. The Post-COVID-19 Functional Status scale: a tool to974measure functional status over time after COVID-19. European975Respiratory Journal; 2020; 56(1).
- 97658.Machado FV, Meys R, Delbressine JM, Vaes, AW, Goërtz YM,977van Herck M, et al. Construct validity of the Post-COVID-19

978 Functional Status Scale in adult subjects with COVID-19. Health 979 and quality of life outcomes.2021;19(1), 1-10.

- 59. Schönhofer B, Ardes P, Geibel M, Köhler D, Jones PW. Evaluation
 of a movement detector to measure daily activity in patients with
 chronic lung disease. Eur Respir J. 1997;10(12):2814-9.
- 983 60. Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M,
 984 Gosselink R. Characteristics of physical activities in daily life in
 985 chronic obstructive pulmonary disease. Am J Respir Crit Care
 986 Med. 2005;171(9):972-7.
- 987 61. Lareau SC, Breslin EH, Meek PM. Functional status instruments:
 988 outcome measure in the evaluation of patients with chronic
 989 obstructive pulmonary disease. Heart Lung. 1996;25(3):212-24.
- 990 62. Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M,
 991 Gosselink R. Physical activity and hospitalization for exacerbation
 992 of COPD. Chest. 2006;129(3):536-44.
- 993 63. Pitta F, Troosters t, Probst VS, Lucas S, Decramer M, Gosselink
 994 R. Potential consequences for stable chronic obstructive
 995 pulmonary disease patients who do not get the recommended
 996 minimum daily amount of physical activity. J Bras Pneumol.
 997 2006;32(4):301-8.
- 99864.Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Antó JM.999Regular physical activity reduces hospital admission and mortality1000in chronic obstructive pulmonary disease: a population based1001cohort study. Thorax. 2006;61(9):772-8.
- 100265.Lareau SC, Meek PM, Roos PJ. Development and testing of the1003modified version of the pulmonary functional status and dyspnea1004questionnaire (PFSDQ-M). Heart Lung. 1998;27(3):159-68.
- 1005 66. 11. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW,
 1006 Wedzicha JA. Usefulness of the Medical Research Council (MRC)
 1007 dyspnoea scale as a measure of disability in patients with chronic
 1008 obstructive pulmonary disease. Thorax. 1999;54(7):581-6.
- 100967.Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha1010JA. Usefulness of the Medical Research Council (MRC) dyspnoea

1011		scale as a measure of disability in patients with chronic obstructive
1012		pulmonary disease. Thorax. 1999;54(7):581-6.
1013	68.	Kovelis D, Segretti NO, Probst VS, Lareau SC, Brunetto AF, Pitta
1014		F. Validation of the Modified Pulmonary Functional Status and
1015		Dyspnea Questionnaire and the Medical Research Council scale
1016		for use in Brazilian patients with chronic obstructive pulmonary
1017		disease. Jornal Brasileiro de pneumologia. 2008;34:1008–18.
1018	69.	ISARIC. ISARIC Covid-19 long term follow up study Tier 1 Initial
1019		Survey First Fallow Up, Oxford, UK, 2021. [cited 2021 Oct 16].
1020		Available from: https://isaric.org/wp-
1021		content/uploads/2021/02/ISARIC_Global_COVID-
1022		19_Long_term_Follow_up_Study_Tier_1_Initial_Survey_first_follo
1023		w_up.PTpdf
1024	70.	ISARIC. ISARIC Covid-19 long term follow up study Tier 1 Initial
1025		Survey First Fallow Up, Oxford, UK, 2021. [cited 2021 Oct 16].
1026		Available from: https://isaric.org/wp-
1027		content/uploads/2021/02/ISARIC_Global_COVID-
1028		19_Long_term_Follow_up_Study_Tier_1_Initial_Survey_first_follo
1029		w_up.PTpdf https://isaric.org/wp-
1030		content/uploads/2021/02/ISARIC_Global_COVID-
1031		19_Long_Term_Follow_up_Study_Tier_1_ONGOING_Survey.PT
1032		pdf
1033	71.	ISARIC. ISARIC Covid-19 long term follow up study Oxford, UK,
1034		2021. [cited 2021 Oct 16]. Available from: Available from:
1035		https://isaric.org/research/covid-19-clinical-research-
1036		resources/follow-up-forms-surveys/
1037	72.	American Thoracic Society/European Respiratory Society.
1038		ATS/ERS Statement on respiratory muscle testing. Am J Respir
1039		Crit Care Med. 2002;166(4):518-624.
1040	73.	Pessoa IM, Houri Neto M, Montemezzo D, Silva LA, Andrade AD,
1041		Parreira VF. Predictive equations for respiratory muscle strength
1042		according to international and Brazilian guidelines. Braz J Phys
1043		Ther. 2014;18(5):410-8.

- 104474.Fess FE. Grip strength. Casanova JS clinical assessment1045recommendations (2nd ed.). American society of hand therapists.10461992;41–5.
- 1047 75. Boadella JM, Kuijer PP, Sluiter JK, Frings-Dresen MH. Effect of
 1048 self-selected handgrip position on maximal handgrip strength.
 1049 Arch Phys Med Rehabil. 2005;86(2):328-31.
- 1050 76. Watanabe T, Owashi K, Kanauchi Y, Mura N, Takahara M, Ogino
 1051 T. The short-term reliability of grip strength measurement and the
 1052 effects of posture and grip span. The Journal of hand surgery.
 1053 2005;30(3):603–9.
- 1054 77. Luna-Heredia E, Martín-Peña G, Ruiz-Galiana J. Handgrip
 1055 dynamometry in healthy adults. Clinical Nutrition. 2005;24(2):250–
 1056 8.
- 105778.Roberts HC, Denison HJ, Martin HJ, et al. A review of the1058measurement of grip strength in clinical and epidemiological1059studies: towards a standardised approach. Age Ageing.10602011;40:423–429.
- 106179.Kleyweg RP, van der Meché FG, Schmitz PI. Interobserver1062agreement in the assessment of muscle strength and functional1063abilities in Guillain-Barré syndrome. Muscle Nerve. 1991;17:1103–10641109.
- 106580.Ciesla N, Dinglas V, Fan E, Kho M, Kuramoto J, Needham D.1066Manual muscle testing: a method of measuring extremity muscle1067strength applied to critically ill patients. J Vis Exp 2011;106812(50):2632.
- 106981.Parry SM, Berney S, Granger CL, Dunlop DL, Murphy L, El-Ansary1070D, et al. A new two-tier strength assessment approach to the1071diagnosis of weakness in intensive care: an observational study.1072Critical Care. 2015;19(1):1–10.
- 107382.Stevens RD, Marshall SA, Cornblath DR, Hoke A, Needham DM,1074de Jonghe B, Ali NA, Sharshar T. A framework for diagnosing and1075classifying intensive care unit-acquired weakness. Crit Care Med.10762009;17:S299–S308.

1077 83. Miyamoto, S. T., Lombardi Júnior, I., Berg, K. O., Ramos, L. R., &
1078 Natour, J. Brazilian version of the Berg balance scale. Brazilian
1079 journal of medical and biological research. 2004;37(9):1411-1421.

- 108084.Podsiadlo D, Richardson S. The timed "Up & Go": a test of basic1081functional mobility for frail elderly persons. J Am Geriatr1082Soc.1991;39:142–148.
- 108385.Mesquita R, Wilke S, Smid DE, Janssen DJA, Franssen FME,1084Probst VS, et al. Measurement properties of the Timed Up & Go1085test in patients with COPD. Chron Respir Dis. 2016;13(4):344–52.
- 108686.Delbressine JM, Vaes AW, Goe"rtz YM, Sillen MJ, Kawagoshi A,1087Meijer K, et al. Effects of ExerciseBased Interventions on Fall Risk1088and Balance in Patients With Chronic Obstructive Pulmonary1089Disease: A systematic review. J Cardiopulm Rehabil Prev. 2020;109040(3):152–63.
- 109187.Rogind, H., Simonsen, H., Era, P., & Bliddal, H. Comparison of1092Kistler 9861A force platform and Chattecx Balance System® for1093measurement of postural sway: correlation and test-retest1094reliability. Scandinavian journal of medicine & science in sports.10952003;13(2):106-114.
- 109688.Gimenez FV, Stadnik AMW, Maldaner M. Analyses of1097Baropodometry Protocols Through Bibliometric Research. Annu1098Int Conf IEEE Eng Med Biol Soc. 2018;2018:3882-3885.
- 109989.Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue1100severity scale: application to patients with multiple sclerosis and1101systemic lupus erythematosus. Archives of neurology.11021989;46(10):1121–3.
- 110390.Krupp LB, Pollina DA. Mechanisms and management of fatigue in1104progressive neurological disorders. Curr Opin Neurol 1996;9:456-1105460.
- 110691.Van de Port IG, Kwakkel G, Schepers VP, Heinemans CT,1107Lindeman E. Is fatigue an independent factor associated with1108activities of daily living, instrumental activities of daily living and1109health-related quality of life in chronic stroke? Cerebrovasc Dis.11102007;23:40–45.

- 1111 92. Valderramas S, Feres AC, Melo A. Reliability and validity study of
 a Brazilian-Portuguese version of the fatigue severity scale in
 Parkinson's disease patients. Arquivos de neuro-psiquiatria.
 2012;70:497–500.
- 1115 93. Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health
 1116 survey (SF-36): I. Conceptual framework and item selection.
 1117 Medical care. 1992;473–83.
- 1118 94. Ciconelli RM, Ferraz MB, Santos W, Meinão I, Quaresma MR.
 1119 Tradução para a língua portuguesa e validação do questionário
 1120 genérico de avaliação de qualidade de vida SF-36 (Brasil SF-36).
 1121 Rev bras reumatol. 1999;39(3):143–50.
- 112295.Temperoni C, Grieco S, Pasquini Z, Canovari B, Polenta A, Gnudi1123U, et al. Clinical characteristics, management and health related1124quality of life in young to middle age adults with COVID-19. BMC1125Infectious Diseases. 2021;21(1):1–10.
- 112696.EQ-5D [Internet]. [cited 2021 Oct 22. Available from:1127https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/
- 112897.EQ-5D-5L. User Guide Basic information on how to use the EQ-11295D-5L instrument. [Internet]. [cited 2021 Oct 22. Available from:1130https://www.unmc.edu/centric/_documents/EQ-5D-5L.pdf
- 113198.Van Hout B, Janssen MF, Feng Y-S, Kohlmann T, Busschbach J,1132Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the1133EQ-5D-5L to EQ-5D-3L value sets. Value in health.11342012;15(5):708–15.
- 1135 99. Alamri HS, Mousa WF, Algarni A, Megahid SF, Al Bshabshe A,
 1136 Alshehri NN, et al. Mental Health of COVID-19 Patients-A Cross1137 Sectional Survey in Saudi Arabia. Int J Environ Res Public Health.
 1138 2021 Apr 29;18(9):4758.
- 1139100. Zigmond AS, Snaith RP. The hospital anxiety and depression1140scale. Acta psychiatrica scandinavica. 1983;67(6):361–70.
- 1141101. Botega NJ, Bio MR, Zomignani MA, Garcia Jr C, Pereira WA.1142Transtornos do humor em enfermaria de clínica médica e1143validação de escala de medida (HAD) de ansiedade e depressão.1144Revista de saude publica. 1995;29:359–63.

1145102.Zung WWK. A self-rating depression scale. Arch Gen Psychiatry.11461965;12:63–70.

- 1147 103. Zung WWK. A rating instrument for anxiety disorders. 1148 Psychosomatics. 1971;12:371–379.
- 1149104.Chagas MHN, Tumas V, Loureiro SR, Hallak JE, Trzesniak C, De1150Sousa JPM, et al. Validity of a Brazilian version of the Zung self-1151rating depression scale for screening of depression in patients with1152Parkinson's disease. Parkinsonism & related disorders. 2010;16(1)
- 1153 105. Weiss DS. The impact of event scale revised. In: Wilson JP, 1154 Keane TM, editors. Assessing psychological trauma and PTSD: a 1155 practitioner's handbook. New York: Guilford Press. 2004;168–89.
- 1156106.Thoresen S, Tambs K, Hussain A, Heir T, Johansen VA, Bisson JI.1157Brief measure of posttraumatic stress reactions: Impact of Event1158Scale-6.11592010;45(3):405–12.
- 1160107. Hosey MM, Leoutsakos J-MS, Li X, Dinglas VD, Bienvenu OJ,1161Parker AM, et al. Screening for posttraumatic stress disorder in1162ARDS survivors: validation of the Impact of Event Scale-6 (IES-6).1163Critical Care. 2019;23(1):1–7.
- 1164108.Vlake JH, Wesselius S, van Genderen ME, van Bommel J,1165Boxma-de Klerk B, Wils EJ. Psychological distress and health-1166related quality of life in patients after hospitalization during the1167COVID-19 pandemic: A single-center, observational study. PLoS1168One. 2021;16(8):e0255774.
- 1169109.Shahin B, Germain M, Pastene G, Viallet N and Annat G.1170Outpatient pulmonary rehabilitation in patients with chronic1171obstructive pulmonary disease. 2008;3(1):155-162.
- 1172110.Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible1173statistical power analysis program for the social, behavioral, and1174biomedical sciences. Behav Res Methods. 2007;39(2):175-91.
- 1175
- 1176

	STUDY PERIOD			
	Enrolment	Allocation	Post- allocation	Close- out
TIMEPOINT (weeks)	-1	0	1-6	7
ENROLMENT:				
Eligibility screen	Х			
Informed consent	Х			
Anthropometric measure				
Allocation medRxiv preprint doi: https://doi.org/10.1101/2022.04.08.22273608; this version posted April 10, 2022. Th (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to INTERVENTIONS is made available under a CC-BY 4.0 International license .	e copyright holder for this p display the preprint in perpe	X reprint tuity.		
Three times per weeks of Outpatient				
Pulmonary Rehabilitation Program combination			v	
of aerobic (bicycle/treadmill) and muscle				
strengthening exercises				
Three times per weeks of Home PRP				
combination of aerobic (walking) and muscle			x	
strengthening exercises				
ASSESSMENTS:				
Primary outcomes				
Pulmonary Function		Х		Х
Exercise Capacity		Х		Х
Status Funcional		Х		Х
Severity of Dyspnea		Х		Х
Secondary outcomes				
Data on physical and psychosocial health and pre-COVID-19 baseline data		х		х
Maximal Inspiratory Pressure		Х		Х
Sympathetic and Parasympathetic Autonomic Activity		x		х
Peripheral Muscle Strength		X		Х
Static Balance Assessment		X		Х
Functional Balance Assessment		х		Х
Functional Mobility		х		х

Muscle Fatigue	X	Х
Quality of Life	X	х
Anxiety and Depression Levels	X	х
Posttraumatic Stress Disorder	X	х





Each week, a new telephone contact will be made asking, about the general health status and guidance regarding the continuity of physical activities.

Figure 2. Study flowchart in accordance with the CONSORT statement.

Figure 2. Study flowchart